Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 2/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29747448 | 1.00 | KDM4E (0.43) | KDM4EGAAAPEX1KMT2ATDP1 | |
| SCHEMBL20867739 | 1.00 | KDM4E (0.43) | KDM4EGAAAPEX1KMT2ATDP1 | |
| SCHEMBL29520407 | 1.00 | KDM4E (0.43) | KDM4EGAAAPEX1KMT2ATDP1 | |
| SCHEMBL20867867 | 1.00 | KDM4E (0.43) | KDM4EGAAAPEX1KMT2ATDP1 | |
| SCHEMBL23085953 | 0.89 | KRAS (0.42) | KDM4EGAAAPEX1KMT2ATDP1 | |
| SCHEMBL23085852 | 0.89 | KRAS (0.42) | KDM4EGAAAPEX1KMT2ATDP1 | |
| SCHEMBL21455302 | 0.85 | KDM4E (0.39) | KDM4EGAAAPEX1KMT2ATDP1 | |
| SCHEMBL23086023 | 0.83 | SOS1 (0.37) | KDM4EGAAAPEX1KMT2ATDP1 | |
| SCHEMBL20867795 | 0.83 | GAA (0.43) | KDM4EGAAAPEX1KMT2ATDP1 | |
| SCHEMBL20867873 | 0.83 | GAA (0.43) | KDM4EGAAAPEX1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153766-A1 | CONDENSED TRICYCLIC COMPOUND USED AS KINASE INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-10968234-B2 | Compound containing tricyclic heteroaryl group | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-10934311-B2 | Heterocyclic compound used as FGFR inhibitor | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20200354376-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| WO-2020188467-A1 | CONDENSED TRICYCLIC COMPOUND USED AS KINASE INHIBITOR | 杭州英创医药科技有限公司 | 2020-09-24 | — | — | WO | disclosed |
| US-10730887-B2 | Compound containing tricyclic heteroaryl group | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-08-04 | — | — | US | disclosed |
| EP-3553064-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2019-10-16 | — | — | EP | disclosed |
| US-20190308993-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-10-10 | — | — | US | disclosed |
| US-20190100531-A1 | HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153766-A1 | CONDENSED TRICYCLIC COMPOUND USED AS KINASE INHIBITOR | HCK, SBK1, ALK | KDM4E 2416/4885GAA 3239/4885APEX1 4445/4885 |
| US-20190308993-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | JAK3, ERBB3, CDK3 | KDM4E 1395/4885GAA 3047/4885APEX1 4787/4885 |
| US-20190100531-A1 | HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | KDM4E 1913/4885GAA 1045/4885APEX1 4466/4885 |
| US-10934311-B2 | Heterocyclic compound used as FGFR inhibitor | FGFR1, FGFR3, FGFR2 | KDM4E 1913/4885GAA 1045/4885APEX1 4466/4885 |
| US-10968234-B2 | Compound containing tricyclic heteroaryl group | JAK3, ERBB3, CDK3 | KDM4E 1533/4885GAA 3217/4885APEX1 4695/4885 |
| US-20200354376-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | JAK3, ERBB3, CDK3 | KDM4E 1533/4885GAA 3217/4885APEX1 4695/4885 |
| US-10730887-B2 | Compound containing tricyclic heteroaryl group | JAK3, ERBB3, CDK3 | KDM4E 1395/4885GAA 3047/4885APEX1 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.